We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 3

Figure 3. Post-relapse survival according to NR3C1 levels at relapse. From: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1.

Graded adverse post-relapse survival effects with progressive loss of NR3C1 expression levels at relapse. 5-yr OS/PFS are noted for each curve, values in parentheses represent the 95% confidence intervals.
P-values: high vs middle, p=0.015; high vs low, p<0.001; middle vs low, p=0.123; low vs mid/high, p<0.001; high vs mid/low, p<0.001

Christoph J Heuck, et al. Clin Cancer Res. ;18(19):5499-5506.
2.
Figure 2

Figure 2. Post-relapse survival related to initial randomization to thalidomide (+T) or control arm (−T). From: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1.

5-yr OS/PFS are noted for each curve, values in parentheses represent the 95% confidence intervals. blue=patients randomized to Thalidomide; red=patients randomized to the control arm.
A: all patients regardless of NR3C1 data Post-relapse survival was independent of intitial randomization to control arm (−T) or thalidomide arm (+T).
B: limited to those with baseline or relapse NR3C1 This also applied to the subset with GEP information, although a trend was observed in favor of longer PRS among patients on the control arm.

Christoph J Heuck, et al. Clin Cancer Res. ;18(19):5499-5506.
3.
Figure 1

Figure 1. Survival outcomes with Total Therapy 2 by treatment arm and NR3C1 expression levels. From: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1.

5-yr OS/PFS are noted for each curve, values in parentheses represent the 95% confidence intervals. Green=low NR3C1 on control arm; yellow= mid/high NR3C1 on control arm; blue= low NR3C1 on the thalidomide arm; red= mid/high NR3C1 on the thalidomide arm
A: Overall survival Low NR3C1 levels conferred inferior survival in patients randomized to the control arm (−T) whereas, in the thalidomide arm (+T), survival was NR3C1 expression-neutral. Green vs. yellow HR= 1.90, p=0.002; blue vs. green, HR=0.54, p=0.015
B: Progression-free survival A similar trend was observed for the control arm (−T) for progression-free survival.
Green vs. yellow, HR=1.47, p=0.03; blue vs. green, HR=0.54, p=0.004

Christoph J Heuck, et al. Clin Cancer Res. ;18(19):5499-5506.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk